If you have recently been diagnosed with Fabry disease, or if you have spent years searching for an explanation for symptoms that no one could identify, this guide is for you. Fabry disease is a rare genetic condition that affects multiple organs in the body and can look very different from one person to the next.

This article explains what Fabry disease is, who it affects, how it progresses, and what your options are after a diagnosis.

What Is Fabry Disease?

Fabry disease is a rare inherited condition in which the body cannot properly break down a fatty substance called GL-3. Without treatment, GL-3 builds up inside cells throughout the body, causing progressive damage to the kidneys, heart, nervous system, and other organs over time.

Every cell in your body contains a tiny recycling system called a lysosome. Lysosomes use specialised enzymes to break down waste products and keep the cell functioning. In Fabry disease, one of those enzymes, called alpha-galactosidase A (shortened to alpha-Gal A), is either missing or not working properly due to a mutation in the GLA gene.

Without alpha-Gal A, a fatty substance called globotriaosylceramide accumulates inside cells. You will see it referred to as GL-3 or Gb3 in medical literature. Think of it like a rubbish collection service that has stopped coming to your neighbourhood. Week after week, the waste builds up. Over months and years, that buildup begins damaging the surrounding structure.

In Fabry disease, that structure is the human body. GL-3 accumulates in the walls of blood vessels and in organs throughout the body, including the kidneys, the heart, the nervous system, the skin, the ears, and the eyes. The damage is progressive and, without treatment, significantly shortens life expectancy.

Fabry disease belongs to a group of conditions called lysosomal storage disorders, defined by the buildup of substances the body cannot process. It is also classified as a rare disease, though research increasingly shows it is far more common than previously believed.

Source: Cleveland Clinic

Who Does Fabry Disease Affect?

Fabry disease affects both men and women. It is caused by a mutation in the GLA gene, which sits on the X chromosome. Because of this inheritance pattern, men and women can experience the condition differently, but both can develop serious, life-affecting symptoms.

The GLA gene sits on the X chromosome, which means Fabry disease follows what geneticists call an X-linked inheritance pattern.

Men have one X chromosome and one Y chromosome. If their single X chromosome carries a GLA mutation, they have no backup copy of the gene, which means they produce little or no functional alpha-Gal A enzyme. Classic Fabry disease in men typically begins in childhood and involves multiple organ systems.

Women have two X chromosomes. If one carries a GLA mutation, the other provides a working copy of the gene. However, a process called lyonisation means that each cell in a woman's body randomly switches off one of its two X chromosomes. Depending on which X chromosome is active in any given organ, a woman with Fabry disease may develop symptoms ranging from mild to just as severe as those seen in men.

Research now confirms that 70 to 80 per cent of women with a GLA mutation develop clinically significant symptoms. Many experience serious kidney, heart, or neurological involvement. Women with Fabry disease have historically been told they are simply carriers of a condition that affects men. That framing is medically wrong and has caused enormous harm. Women with Fabry disease are patients.

How Common Is Fabry Disease?

Fabry disease is more common than official statistics suggest. Classic estimates put the prevalence at around 1 in 40,000 to 60,000 males, but newborn screening studies indicate the true prevalence, including all variants, may be closer to 1 in 1,500 to 1 in 9,000 people worldwide.

The discrepancy exists because for decades, only the most severe classic presentations were being diagnosed. Late-onset variants, which involve milder or organ-specific disease, were routinely missed. As newborn screening programmes expanded, researchers found GLA mutations at far higher rates than expected.

Many individuals with late-onset Fabry variants will develop significant cardiac or kidney disease in middle age without ever knowing the underlying cause, unless they receive a Fabry diagnosis first.

Classic Fabry Disease versus Late-Onset Fabry Disease

There are two main presentations of Fabry disease. Classic Fabry begins in childhood with widespread organ involvement. Late-onset Fabry develops in adulthood and typically affects one or two organs, most commonly the heart or kidneys. Both are serious and both require specialist management.

Classic Fabry Disease

Symptoms in classic Fabry disease typically begin between the ages of 3 and 10. Children with classic Fabry often experience severe burning pain in their hands and feet, an inability to sweat normally, gastrointestinal problems, and small raised spots on the skin called angiokeratomas. Classic Fabry involves very little residual enzyme activity, typically less than 1 per cent of normal levels.

Without treatment, classic Fabry significantly shortens life expectancy. Children and teenagers with classic Fabry frequently spend years being dismissed, told their pain is growing pains, anxiety, or something they are imagining. The average time from first symptom to correct diagnosis is 10 to 16 years.

Late-Onset Fabry Disease

Late-onset Fabry appears in adulthood, often in the 30s to 60s. Patients retain some residual enzyme activity, typically between 2 and 30 per cent of normal, which delays and localises the damage. The most common presentations are unexplained thickening of the heart muscle (a condition called left ventricular hypertrophy) and progressive kidney disease.

Many patients with late-onset Fabry are diagnosed only after being investigated for an unrelated cardiac or renal problem. Late-onset Fabry represents approximately 60 to 70 per cent of all Fabry diagnoses and remains massively underdiagnosed.

If you or someone in your family has been told they have unexplained heart or kidney problems, Fabry disease is worth raising with a specialist, particularly if there is a family history of similar issues.

How Fabry Disease Progresses and Which Organs It Affects

Fabry disease is a multi-organ condition. GL-3 accumulates in blood vessel walls throughout the body, causing progressive damage to the kidneys, heart, nervous system, gastrointestinal tract, skin, hearing, and eyes. The severity and timeline of organ involvement varies between individuals.

1. The Nervous System and Pain
   The earliest and most distinctive symptom in classic Fabry disease is neuropathic pain, a burning or stabbing sensation in the hands and feet known as acroparesthesia. Patients describe it as walking on broken glass, or feeling like their extremities are permanently on fire. This pain can be constant at a low level with episodes of severe crisis pain triggered by heat, exercise, fever, or emotional stress.
   
   Many patients with Fabry disease also cannot sweat normally, a condition called anhidrosis or hypohidrosis, because GL-3 damages the sweat glands. This means the body struggles to regulate temperature. Heat, exercise, and warm environments can trigger severe pain episodes and dangerous overheating. Children with Fabry disease are often the children who could never play sports, who sat out of physical education class, who were called lazy or dramatic.

2. The Kidneys
   The kidneys are one of the primary organs affected by GL-3 accumulation. Kidney damage begins silently, often showing up first as protein in the urine during the teenage years or early adulthood. Without treatment, many patients with classic Fabry disease progress to end-stage kidney disease requiring dialysis or transplantation by their 30s or 40s. Early treatment with enzyme replacement therapy can slow this progression significantly.

3. The Heart
   Cardiac involvement is the most common cause of death in Fabry patients today. GL-3 accumulates in heart muscle cells, causing the walls of the heart to thicken, a condition called left ventricular hypertrophy. This leads to arrhythmias, heart failure, and sudden cardiac death.
   
   Cardiac Fabry is also the most common late-onset presentation. Research suggests that approximately 1 to 4 per cent of patients with unexplained left ventricular hypertrophy may have undiagnosed Fabry disease. If you or a family member has been told they have an unexplained thickened heart muscle, this is worth discussing with a cardiologist familiar with lysosomal storage disorders.

4. The Gastrointestinal Tract
   Abdominal pain, cramping, diarrhoea, nausea, and bloating affect an estimated 50 to 70 per cent of patients with Fabry disease. These symptoms are frequently misdiagnosed as irritable bowel syndrome, Crohn's disease, or anxiety. For some patients, gastrointestinal symptoms are the most disabling aspect of their daily life.

5. Stroke Risk
   Fabry patients have a significantly elevated stroke risk. Strokes can occur at unusually young ages, sometimes in the 20s or 30s. Research suggests that approximately 4 to 5 per cent of young adult strokes with no identified cause may be attributable to undiagnosed Fabry disease. If you or a family member has experienced a stroke at a young age with no clear explanation, Fabry disease is worth investigating.

6. Other Symptoms
   Several other features are common in Fabry disease and can serve as diagnostic clues. Cornea verticillata is a whorl-like pattern visible on the cornea under slit lamp examination, present in most patients. It does not affect vision but is a reliable diagnostic indicator. Small dark raised spots on the skin called angiokeratomas typically appear around the hips, groin, and navel area. High-frequency hearing loss and tinnitus affect many patients. Chronic fatigue that is disproportionate to visible illness is nearly universal and is one of the most consistently reported aspects of living with Fabry disease.

If you or someone in your family has recently been diagnosed with Fabry disease, our free guide walks you through what to expect, which questions to ask your specialist, and how to start managing your health one step at a time.
Download our app on the Google Play Store or App Store

What Happens After a Fabry Diagnosis?

A Fabry diagnosis opens the door to treatment, specialist monitoring, and family testing. Two disease-specific treatments are currently available: enzyme replacement therapy delivered by infusion, and an oral therapy called migalastat. A specialist team will guide which option is appropriate based on your specific GLA mutation and organ involvement.

Enzyme Replacement Therapy

Enzyme replacement therapy (ERT) provides the body with a manufactured version of the missing alpha-Gal A enzyme, delivered intravenously. Two products are available: agalsidase beta (Fabrazyme) and agalsidase alfa (Replagal). ERT is administered every two weeks for life, with infusions typically taking two to four hours. It does not cure Fabry disease, but when started early it slows the progression of organ damage significantly.

The infusion schedule is one of the most disruptive aspects of Fabry management. Every two weeks, a patient sits in an infusion chair for two to four hours. Over years and decades, this becomes a defining feature of life with Fabry. The FabryApp Binder can help you journal infusion days, track how you feel before and after, and note any reactions to share with your care team.

Migalastat (Galafold)

Migalastat is an oral medication taken every other day. Rather than replacing the missing enzyme, it helps the patient's own misfolded alpha-Gal A fold correctly so it can function. It is only suitable for patients with specific GLA mutations, approximately 35 to 50 per cent of all known mutations. A genetic amenability test confirms eligibility before treatment begins.

For patients who are eligible, migalastat represents a significant improvement in quality of life. No infusions, no IV lines, no hours in a chair every two weeks. One capsule, every other day.

Testing Your Family

A Fabry diagnosis is not just an individual event. Because Fabry is X linked, other family members are at risk. On average, one Fabry diagnosis leads to five additional family members being identified with the condition across multiple generations.

A mother with Fabry has a 50 per cent chance of passing the gene mutation to each child, regardless of the child's sex. A father with Fabry will pass the gene to all of his daughters and none of his sons. A genetic counsellor can help map your family's inheritance pattern and guide conversations about who should be tested and when.

These conversations are not easy. Family members may be in denial, may not want to know, or may live in different countries with different access to testing. Taking it one step at a time and working with a genetic counsellor makes the process more manageable.